Dana-Farber-Cancer Institute Inc.

The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

The Broad Institute, Inc.

Enzon Pharmaceuticals, Inc.

The General Hospital Corporation D/b/a Massachusetts General Hospital

Christopher J Ott

James Elliott Bradner

Zhengxing Qu

Bradley Bernstein

Yixian Zhang

Lee Greenberger

Jon C Aster

David Root

Birgit Knoechel

Rajanikanth Bandaru

Bradley E Bernstein

The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.

Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy

The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.

LNA antisense oligonucleotides for the modulation of Myc expression

Growing community of inventors

Cambridge, MA, United States of America

Christopher J Ott